Association of Methylated DNA Markers with High-Risk HPV Infections in Oral Site and Precancer Anal Lesions in HIV-Positive MSM
by
, and
Silvia Pauciullo
1,
Daniele Colombo
2,
Verdiana Zulian
1,
Roberta Sciamanna
1,
Antonio Coppola
1,
Alessandra Scarabello
3,
Franca Del Nonno
2 and
Anna Rosa Garbuglia
1,*
1
Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy
2
Pathology Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy
3
Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(8), 1838; https://doi.org/10.3390/biomedicines12081838
Submission received: 24 July 2024
/
Revised: 7 August 2024
/
Accepted: 9 August 2024
/
Published: 13 August 2024
(This article belongs to the Special Issue Current Perspectives on Human Papillomavirus (HPV))
Abstract
:Background: Human papillomavirus (HPV) infection is linked to several cancers, including anal and oral cancers. The incidence of anal cancer is particularly high among HIV-positive men who have sex with men (MSM). DNA methylation markers have shown promise as biomarkers for identifying precancerous lesions and cancer in HPV-infected individuals. The aim of this study was to investigate the correlation of DNA methylation with HPV infection in oral samples and the correlation of DNA methylation with lesion degree in the anal samples of HIV-positive MSM. Methods: This study investigated DNA methylation in oral and anal samples from HIV-positive MSM at the National Institute for Infectious Diseases (INMI) in Rome, Italy. Exfoliated oral epithelial cells and anal samples were collected and analyzed for 28 HPV genotypes using the Allplex 28 HPV assay. DNA methylation was assessed with the PrecursorM+ kit for oral samples and the AnoGyn kit for anal samples, focusing on the promoter regions of specific genes. Results: The study included 63 participants, with a median age of 49 and a median CD4+ count of 705 cells/µL. The oral samples showed HPV16 as the most common type, with 22% testing positive for DNA methylation. The anal samples exhibited HPV-related methylation changes linked to cytological lesions, with a 30% increase in the observed ddCt ratio. Significant differences were found in both ASCL1 and ZNF582 genes, particularly for HSILvsNILM and HSILvsLSIL lesions. Of the samples with an increased ddCt ratio, 80% were from patients over 35 years old, and multiple HPV infections were common. Conclusions: DNA methylation markers could be valuable in identifying high-risk HPV infections in oral samples and detecting potential precancerous lesions in anal samples. These markers may enhance the early detection and prevention strategies for HPV-related cancers in high-risk populations, with follow-up data indicating potential for monitoring lesion progression.
1. Introduction
Human papillomavirus (HPV) infection had been recognized as causal agent or various cancers beyond cervical cancer, including head and neck cancers (HNCs), and neoplasms of the anus, vagina, and penis with different prevalence [1]. In men, >90% of anal cancers are HPV-positive, particularly for HPV16 [2], with squamous cell carcinoma (SCC) being the most common malignant neoplasia affecting the anal canal [3,4]. Most HPV-related SCCs develop from dysplastic squamous precursor lesions, making early identification crucial for preventing malignant neoplasia. The incidence of anal cancer is significantly higher in high-risk populations, such as people living with HIV (PLWH), men who have sex with men (MSM), and women with a history of HPV-related cervical precancerous lesions, with a cancer rates 4 to 50 times higher compared to the general population [5,6]. In particular, MSM aged over 35 living with HIV have an anal cancer incidence ten times higher than the general population, with a prevalence of 54.6% for anal high-grade squamous intraepithelial lesions (HSILs) [7]. Among these, an estimated 10% of anal HSIL cases progress to anal cancer [8]. The HPV prevalence in HNCs varies, with HPV DNA positivity rates of 24.2% in oral cancers [9] and 30.1% in oral squamous cell carcinoma (OSCC) [10]. The prevention strategies for HPV-related cancers differ by tumour type. For anal cancer, screening programmes often include anal cytology and high-resolution anoscopy (HRA) with biopsies of suspected lesions, similarly to cervical screening for the early diagnosis and treatment of premalignant lesions [11]. However, the effectiveness of screening for reducing anal cancer incidence remains uncertain [12]. The Anal Cancer–HSIL Outcomes Research (ANCHOR) study recently showed that treating HSILs reduces the incidence of anal squamous cell carcinoma (ASCC) by 57% compared to no treatment with close monitoring [13] and earlier treatment could facilitate a reduction in the development of anal cancer. In contrast, no established screening strategies exist for oral and oropharyngeal cancers, despite their rising incidence in PLWH. Limited data are available on the predictors of oral HPV infections and related lesions, and their correlation with anal HPV infections in this at-risk group, and the utility of oral cytology and oroscopy in detecting oral cancer precursors, is unknown [11]. The natural history of HPV-caused oropharyngeal cancer is understudied, with no recognized precancerous lesions, thus making secondary prevention challenging. To optimize the prevention and screening for oral and anal HPV-related cancers, additional biomarkers, such as DNA methylation, could be valuable. DNA methylation suppresses the gene expression involved in cell cycle arrest and terminal differentiation in epithelial cells [14]. HPV can stimulate host DNA methylation by E6 and E7 proteins, enhancing the expression of the DNA methyltransferase (DNMT) [14,15], which increases DNA instability, leading to the oncogene expression and inactivation of tumour suppressor activity [16]. Higher DNA methylation levels in HPV-positive individuals have been noted across various HPV-related tumours [17]. Nakagawa et al. highlight distinct DNA methylation patterns in HPV-associated head and neck squamous cell carcinoma (HNSCC) compared to HPV-negative cases. Tumours without HPV integration exhibit high DNA methylation and better prognosis, whereas those with HPV integration show intermediate methylation and worse outcomes [17].
Altogether, these findings suggest that specific epigenetic changes could aid in developing targeted therapies and improving patient stratification.
The aims of this study were to describe the role of DNA methylation gene in oral samples infected with low-risk (LR) and high-risk (HR) HPV genotypes in a cohort of HIV-infected MSM who attended the Sexually Transmitted Disease Care Unit at INMI L Spallanzani. We also explored the host methylation correlation with anal HPV-correlated lesion in the same patients.
2. Materials and Methods
The study included HIV-positive MSM attending the Sexually Transmitted Disease Care Unit. HIV-positive MSM who resulted HPV positive in oral sample were consecutively included from September 2023 to April 2024. A DNA methylation test was performed both in oral and anal samples in each patient.
Specimen collection, processing, and DNA purification. Exfoliated oral epithelial cells were collected via oral rinse and gargle with mineral water, as previously described [18]. A physician also collected anal samples by using saline-moistened swabs [18]. For each patient, the following variables were recorded: age, CD4+ T cell count, actual viral load, and antiretroviral treatment. DNA was isolated from oral rinse and anal swabs using a magnetic bead-based automated platform QIASYMPPHONY (QIAGEN, Hilden, Germany). Purified DNA was evaluated for the presence of 28 HPV genotypes by the use of an Allplex 28 HPV SEEGENE real-time assay (SEEGENE, Seoul, Republic of Korea). HPV types were classified into non-oncogenic (low-risk, LR HPV6,11,26,40,42,43,44,54,61,70) and HR/potential carcinogenic (HPV16,18,26,31,33,35,39,45,51,52,53,56,58,59,68,69,73,82). Allplex HPV28 detection assays were performed using a CFX real-time thermocycler (Bio-Rad, Hercules, CA, USA). A Cq cut-off value of 42.00 was used for positivity for all HPV genotypes.
Cytology. The anal and oral samples were also used to perform cytology analysis. The cytology results were classified as normal, atypical squamous cells of uncertain significance (ASCUS), atypical squamous cells cannot exclude HSIL (ASC-H), low grade squamous intraepithelial lesion (LSIL), high-grade squamous lesion (HSIL), and squamous cell carcinoma (SCC), in accordance with the Bethesda classification system [19].
DNA methylation marker analysis. The DNA methylation analysis was carried out with two different commercially available diagnostic kits: the CE-IVD PrecursorM+ kit (distributed by Fujirebio Europe, Gent, Belgium) for oral samples, using this type of application outside of the manufacturer’s indications; the RUO AnoGyn kit (distributed by Fujirebio Europe), for the analysis carried out on anal samples. The PreCursorM+ Assay analyses in a multiplex methylation-specific real-time PCR the methylation of the promoter regions of FAM19A4 and miR124-2, and the ACTB gene, encoding for beta-actin, as a reference gene. Instead, the AnoGyn kit analyzes, in a multiplex methylation-specific real-time PCR, the methylation of the promoter regions of ASCL1 and ZNF582 and a reference gene (ACTB). Briefly, genomic DNA was isolated as described above and its concentration measured with the Qubit™ 4 Fluorometer Instrument (Thermo Fisher, Waltham, MA, USA) using the Qubit 1X dsDNA BR Assay Kit (Thermo Fisher), an assay designed to measure the genomic DNA concentration in a range of 4–4000 ng. In the bisulfite reaction up to 200 ng/45 μL, isolated genomic DNA was converted using the EZ DNA Methylation Kit (Zymo Research Europe, Freiburg im Breisgau, Germany) following the manufacturer’s instructions.
To perform both PreCursorM+ and AnoGyn Test, 17.5 μL of the respective ready-to-use real-time PCR Master Mix and 2.5 μL of DNA-positive and -negative controls were added to PCR instrument tubes. The multiplex PCR was run on a MIC IVD instrument (Bio Molecular Solutions, Upper Coomera, QLD, Australia).
The samples were scored as valid when the Ct value of ACTB was ≤26.4 for the PreCursorM+ and when the Ct value of ACTB was ≤30 for the AnoGyn, according to manufacturer instructions. For both kits, the ΔΔCt values for each target gene were calculated with the following formula: ΔΔCt target gene = (Ct target gene sample − Ct ACTB sample) − (Ct target gene calibrator − Ct ACTB calibrator). For the PrecursorM+ analysis, oral samples were considered hypermethylation-positive if at least one of the methylation marker genes had a ΔΔCt below the cut-off that the manufacturer provide for analysis of cervical self-collected samples (10.36 for FAM19A4 and 6.5 for miR124-2). These cut-offs were applied empirically, as there is currently no supporting literature on samples taken from the oral cavity. For the AnoGyn Analysis, given that the kit is available on the market as RUO, there are no pre-established cut-offs that can be applied even empirically. The methylation level of a target in anal samples is expressed as the ‘ΔΔCt ratio’ (2−ΔΔCt * 100). The interpretation was performed using an incremental increasing scale starting at 0, in which 0 indicates no methylation, and increasing numbers indicate higher methylation levels.
Statistical analyses. Statistical analyses and graphical representations were performed using GraphPad Prism version 9 (GraphPad Software, La Jolla, CA, USA). A significance level of p < 0.05 was chosen for all statistical tests.
The categorical variables were given as numbers and percentages, and the continuous variables as median values and interquartile range (IQR). Fisher’s exact test was used to examine the association between methylation positivity vs. multi-genotype HPV infection. An unpaired Mann–Whitney test was used to compare the ddCt ratio of ASCL1 and ZNF582 genes between the several lesion grades (NILM, ASCUS/ASC-H, LSIL, and HSIL).
3. Results
The characteristics of the 63 participants included in the study are shown in Table 1. All participants were receiving HAART with a current median CD4+ T cell count of 705 cells/μL and a median age of 49 years (Table 1); the majority of participants had an HIV RNA viral load <30 copies/mL (80.9%). Figure 1 shows the distribution of the detected HPV genotypes.
3.1. Oral Samples
Concerning oral site (Table 2), a total of 50 samples were analyzed with the PrecursorM+ assay, whereas 13 specimens were excluded because the DNA sample volume was not sufficient for the bisulfite conversion step (n = 11) or because ACTB gave no amplification signal (n = 2). A total of 44 specimens harboured at least one HR-HPV or probable carcinogenic HPV types, with the HPV16 being the most represented (n = 10). Multiple HPV infections were observed in 15 samples. No neoplastic lesions were observed in any oral samples.
Among 50 oral samples, 11 (22.00%) were considered positive for methylation. The prevalence of methylation positivity in these samples was 9.09% for LR-HPV and 90.91% for HR-HPV. However, the differences in methylation prevalence compared to the methylation-negative samples were not statistically significant (p = 0.66).
In samples considered as positive for DNA methylation, the median age was 57 years, and the CD4+ T cell count was 747 cells/µL (618.5–997.5), which did not differ from the median value (p > 0.05). Additionally, the exact Fisher’s test analysis highlighted no statistical significance (p > 0.9999) for oral samples in relation to the association between methylation positivity and multi-genotype HPV infection.
Four patients also presented follow-up samples; thus, overall, we analyzed 54 oral specimens. The ages of these patients were as follows: 56 years (y) (FU14), 49 y (FU31), and 29 y (FU34 and FU44). Pt 14, who showed DNA methylation on the FAM19A4 gene in both samples, was infected with HPV61, whereas the other three couple samples with follow-up (Pt 14-FU14; Pt 31-FU31; Pt 34-FU34; Pt 44-FU44) showed no methylation in both time points. A second HPV61-positive patient (Pt 41) was positive for DNA methylation. No oral neoplastic lesions were observed among any patients.
3.2. Anal Samples
Among the 63 anal specimens analyzed for DNA methylation with the AnoGyn kit, 33 were excluded because the amount of DNA was not sufficient for the bisulfite conversion step (n = 20) or because ACTB gave no amplification signal (n = 13). A total of 35 specimens harboured at least one HR-HPV or probable carcinogenic HPV types. HPV multiple infection was observed in 33 samples. The results obtained are shown in Figure 2. The samples were divided by cytological category: 11 NILM (absence of lesions), 4 ASCUS and 4 ASC-H (grouped into a single category), 5 LSIL, and 6 HSIL; it is also possible to observe how each cytological category presents a different distribution of the ddCt ratio, which increases as the lesion is observed. An increased ddCt ratio was observed in 30% of the anal samples analyzed (n = 10); 10% of these samples were associated with LR-HPV (n = 1), 90% were associated with HR-HPV (n = 9), and 50% exhibited an HSIL (n = 5), with methylation that seems more pronounced for the ZNF582 gene than for the ASCL1 gene.
In addition, there were statistically significant differences in the ddCt ratio as follows: (1) ASCL1 gene in HSIL vs. NILM (p = 0.0007) and HSIL vs. LSIL (p = 0.026); (2) ZNF582 gene in HSIL vs. NILM (p = 0.001) and HSIL vs. LSIL (p = 0.0043).
Furthermore, 80% of the samples with an increased ddCt ratio showed the presence of multiple infections (n = 8).
The median age of samples with an increased ddCt ratio was 50.5 versus 47 years in samples with a ddCt ratio near to zero, while the median CD4+ T cell count was 578 (450.0–782.5) and 692 (157–749) cells/μL, respectively. Finally, among the samples with an increased ddCt ratio, 90% (n = 9) were from patients aged over 35 years, while 10% (n = 1) were associated with patients aged under 35 years.
4. Discussion
The findings shown in the present study, though preliminary, offer valuable insights into the potential use of DNA methylation testing in preventing HPV-related oral and pharyngeal tumours. Among our patients, all but two who tested positive for DNA methylation were infected with HR-HPV in oral samples. Interestingly, HPV61, typically considered low-risk for genital and anal infections, was found in samples of HNC and anal carcinoma [20,21]. Further evidence is needed to clarify HPV61’s oncogenic role, particularly in the oropharyngeal region. However, during the follow-up, Pt 14 also tested positive for HR-HPV52 (Table 2), which may have facilitated the persistence of the hypermethylation status.
It is important to note that our observation of four follow-up samples confirmed previous findings, suggesting that HPV transformation in the oral cavity could occur gradually over at least six months following the initial detection. Indeed, no significant changes in methylation status were observed in any six-month follow-up, and positivity for DNA methylation (Pt 14) was confirmed in subsequent follow-up samples. There was no correlation between oral and anal methylation status. At the anal level, methylation status could serve as a parameter for determining the intervals for cytological testing or high-resolution anoscopy (HRA) in cases of HR-HPV presence, and this biomarker could prove particularly useful in settings where HRA infrastructure is limited for referring patients with abnormal screening results. Additionally, it may provide a further interpretation of ASCUS cases where abnormal cytological findings do not offer sufficient indications of clinical impact. Our data confirm those reported in the study by Rozemeijer et al., wherein a greater degree of methylation was observed in subjects with HSIL compared to those with LSIL and ASCUS [22], and in the work by Vasavada, who analyzed the DNA methylation of different genes: ASCL1 and FMN2 [23]. Furthermore, over 90% of the patients with an increased ddCt ratio in anal samples were aged >35 years. This observation supports the IANS recommendation to initiate anal cancer screening for HIV-positive MSM aged >35 years [24]. One of the limitations of our study is the choice of cut-off values. Specifically, the cut-offs used in our analysis were not originally defined for DNA methylation in the sites investigated in our preliminary study. Instead, we used cut-off values that were established for the uterine cervix. To provide new insights on cut-off definition, additional patients will be enrolled in a longitudinal follow-up study to verify the use of these biomarkers in the prevention of HPV-related SCC in the oral cavity.
Consequently, one of our future objectives is to implement and clearly define cut-offs that can be used according to the specific site being analyzed; alternatively, the cut-offs may be applicable to both anatomical sites.
Other limitations of this study include the small number of patients and follow-up samples from the oral cavity. However, the association of all oral methylation-positive samples with HR-HPV is encouraging for conducting longitudinal studies that incorporate DNA methylation testing into screening protocols. For anal samples, associating DNA methylation results with HRA findings may provide necessary insights into the relevance of this new test as a predictor of HPV oncogenic transformation.
Author Contributions
Writing—original draft preparation, S.P. and A.R.G.; methodology, D.C., F.D.N., A.S. and V.Z.; collecting samples for HPV genotyping, R.S. and A.C.; writing—review and editing A.R.G., S.P. and V.Z.; funding acquisition, A.R.G. All authors have read and agreed to the published version of the manuscript.
Funding
This study was funded by Ricerca corrente Ministero della Salute and Methylation DNA assay used in this study were supported by Fujirebio. The funding sources had no role in any part of the study design, data collection/analysis/interpretation, report writing, or decision to publish.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of INMI L Spallanzani (protocol code number42_13, date of approval on 18 June 2013).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
| ACTB | β-actin |
| AIN | anal intraepithelial neoplasia |
| ASC-H | atypical squamous cells cannot exclude HSIL |
| ASCL1 | achaete-scute family bHLH transcription factor 1 |
| ASCUS | atypical squamous cells of undetermined significance |
| CI | confidence interval |
| Cq | quantification cycle |
| DNMT | DNA methyltransferase |
| FAM19A4 | family with sequence similarity 19 member A4 |
| FMN2 | formin 2 |
| HAART | highly active antiretroviral therapy |
| HGAIN | high-grade anal intraepithelial neoplasia |
| HIV | human immunodeficiency virus |
| HNC | head and neck cancer |
| HPV | human papillomavirus |
| HRA | high-resolution anoscopy |
| HR-HPV | high-risk human papillomavirus |
| HSIL | high-grade squamous intraepithelial lesion |
| IANS | International Anal Neoplasia Society |
| IQR | interquartile range |
| LR-HPV | low-risk human papillomavirus |
| LSIL | low-grade squamous intraepithelial lesion |
| Mir124-2 | microRNA 124-2 |
| MSM | men who have sex with men |
| NILM | negative for intraepithelial lesion or malignancy |
| PCR | polymerase chain reaction |
| PLWH | people living with HIV |
| RUO | research use only |
| SCC | squamous cell carcinoma |
| ZNF582 | zinc finger protein 582 |
References
- Garbuglia, A.R.; Lapa, D.; Sias, C.; Capobianchi, M.R.; Del Porto, P. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front. Immunol. 2020, 11, 188. [Google Scholar] [CrossRef] [PubMed]
- Vincent-Salomon, A.; de la Rochefordière, A.; Salmon, R.; Validire, P.; Zafrani, B.; Sastre-Garau, X. Frequent Association of Human Papillomavirus 16 and 18 DNA with Anal Squamous Cell and Basaloid Carcinoma. Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc 1996, 9, 614–620. [Google Scholar]
- Morton, M.; Melnitchouk, N.; Bleday, R. Squamous Cell Carcinoma of the Anal Canal. Curr. Probl. Cancer 2018, 42, 486–492. [Google Scholar] [CrossRef] [PubMed]
- Klas, J.V.; Rothenberger, D.A.; Wong, W.D.; Madoff, R.D. Malignant Tumors of the Anal Canal: The Spectrum of Disease, Treatment, and Outcomes. Cancer 1999, 85, 1686–1693. [Google Scholar] [CrossRef]
- Colón-López, V.; Shiels, M.S.; Machin, M.; Ortiz, A.P.; Strickler, H.; Castle, P.E.; Pfeiffer, R.M.; Engels, E.A. Anal Cancer Risk Among People with HIV Infection in the United States. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018, 36, 68–75. [Google Scholar] [CrossRef] [PubMed]
- Clifford, G.M.; Georges, D.; Shiels, M.S.; Engels, E.A.; Albuquerque, A.; Poynten, I.M.; de Pokomandy, A.; Easson, A.M.; Stier, E.A. A Meta-Analysis of Anal Cancer Incidence by Risk Group: Toward a Unified Anal Cancer Risk Scale. Int. J. Cancer 2021, 148, 38–47. [Google Scholar] [CrossRef] [PubMed]
- Wei, F.; Gaisa, M.M.; D’Souza, G.; Xia, N.; Giuliano, A.R.; Hawes, S.E.; Gao, L.; Cheng, S.-H.; Donà, M.G.; Goldstone, S.E.; et al. Epidemiology of Anal Human Papillomavirus Infection and High-Grade Squamous Intraepithelial Lesions in 29 900 Men According to HIV Status, Sexuality, and Age: A Collaborative Pooled Analysis of 64 Studies. Lancet HIV 2021, 8, e531–e543. [Google Scholar] [CrossRef] [PubMed]
- Berry, J.M.; Jay, N.; Cranston, R.D.; Darragh, T.M.; Holly, E.A.; Welton, M.L.; Palefsky, J.M. Progression of Anal High-Grade Squamous Intraepithelial Lesions to Invasive Anal Cancer among HIV-Infected Men Who Have Sex with Men. Int. J. Cancer 2014, 134, 1147–1155. [Google Scholar] [CrossRef] [PubMed]
- Ndiaye, C.; Mena, M.; Alemany, L.; Arbyn, M.; Castellsagué, X.; Laporte, L.; Bosch, F.X.; de Sanjosé, S.; Trottier, H. HPV DNA, E6/E7 mRNA, and p16INK4a Detection in Head and Neck Cancers: A Systematic Review and Meta-Analysis. Lancet Oncol. 2014, 15, 1319–1331. [Google Scholar] [CrossRef]
- Kansy, K.; Thiele, O.; Freier, K. The Role of Human Papillomavirus in Oral Squamous Cell Carcinoma: Myth and Reality. Oral Maxillofac. Surg. 2014, 18, 165–172. [Google Scholar] [CrossRef]
- Cachay, E.R.; Mathews, W.C. Human Papillomavirus, Anal Cancer, and Screening Considerations among HIV-Infected Individuals. AIDS Rev. 2013, 15, 122–133. [Google Scholar] [PubMed]
- Siddharthan, R.V.; Lanciault, C.; Tsikitis, V.L. Anal Intraepithelial Neoplasia: Diagnosis, Screening, and Treatment. Ann. Gastroenterol. 2019, 32, 257–263. [Google Scholar] [CrossRef] [PubMed]
- Palefsky, J.M.; Lee, J.Y.; Jay, N.; Goldstone, S.E.; Darragh, T.M.; Dunlevy, H.A.; Rosa-Cunha, I.; Arons, A.; Pugliese, J.C.; Vena, D.; et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N. Engl. J. Med. 2022, 386, 2273–2282. [Google Scholar] [CrossRef] [PubMed]
- Orioli, D.; Dellambra, E. Epigenetic Regulation of Skin Cells in Natural Aging and Premature Aging Diseases. Cells 2018, 7, 268. [Google Scholar] [CrossRef] [PubMed]
- Burgers, W.A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F. Viral Oncoproteins Target the DNA Methyltransferases. Oncogene 2007, 26, 1650–1655. [Google Scholar] [CrossRef] [PubMed]
- Steenbergen, R.D.M.; Snijders, P.J.F.; Heideman, D.A.M.; Meijer, C.J.L.M. Clinical Implications of (Epi)Genetic Changes in HPV-Induced Cervical Precancerous Lesions. Nat. Rev. Cancer 2014, 14, 395–405. [Google Scholar] [CrossRef] [PubMed]
- Nakagawa, T.; Kurokawa, T.; Mima, M.; Imamoto, S.; Mizokami, H.; Kondo, S.; Okamoto, Y.; Misawa, K.; Hanazawa, T.; Kaneda, A. DNA Methylation and HPV-Associated Head and Neck Cancer. Microorganisms 2021, 9, 801. [Google Scholar] [CrossRef] [PubMed]
- Vergori, A.; Garbuglia, A.R.; Piselli, P.; Del Nonno, F.; Sias, C.; Lupi, F.; Lapa, D.; Baiocchini, A.; Cimaglia, C.; Gentile, M.; et al. Oral Human Papillomavirus DNA Detection in HIV-Positive Men: Prevalence, Predictors, and Co-Occurrence at Anal Site. BMC Infect. Dis. 2018, 18, 25. [Google Scholar] [CrossRef] [PubMed]
- The 1988 Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. Developed and Approved at the National Cancer Institute Workshop, Bethesda, Maryland, U.S.A., December 12–13, 1988. Acta Cytol. 1989, 33, 567–574. [Google Scholar]
- Félez-Sánchez, M.; Vergara, M.; de Sanjosé, S.; Castellsagué, X.; Alemany, L.; Bravo, I.G.; VVAPO/RIS HPV TT Study Groups. Searching beyond the Usual Papillomavirus Suspects in Squamous Carcinomas of the Vulva, Penis and Head and Neck. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2016, 45, 198–204. [Google Scholar] [CrossRef]
- Komloš, K.F.; Kocjan, B.J.; Košorok, P.; Rus, T.; Toplak, J.; Bunič, M.; Poljak, M. Distribution of HPV Genotypes in Slovenian Patients with Anal Carcinoma: Preliminary Results. Acta Dermatovenerol. Alp. Pannonica Adriat. 2011, 20, 141–143. [Google Scholar] [PubMed]
- Rozemeijer, K.; Dias Gonçalves Lima, F.; Ter Braak, T.J.; Hesselink, A.T.; Prins, J.M.; de Vries, H.J.C.; Steenbergen, R.D.M. Analytical Validation and Diagnostic Performance of the ASCL1/ZNF582 Methylation Test for Detection of High-Grade Anal Intraepithelial Neoplasia and Anal Cancer. Tumour Virus Res. 2024, 17, 200275. [Google Scholar] [CrossRef] [PubMed]
- Vasavada, A.; Stankiewicz Karita, H.C.; Lin, J.; Schouten, J.; Hawes, S.E.; Barnabas, R.V.; Wasserheit, J.; Feng, Q.; Winer, R.L. Methylation Markers for Anal Cancer Screening: A Repeated Cross-sectional Analysis of People Living with HIV, 2015–2016. Int. J. Cancer 2024, 155, 1091–1100. [Google Scholar] [CrossRef] [PubMed]
- Stier, E.A.; Clarke, M.A.; Deshmukh, A.A.; Wentzensen, N.; Liu, Y.; Poynten, I.M.; Cavallari, E.N.; Fink, V.; Barroso, L.F.; Clifford, G.M.; et al. International Anal Neoplasia Society’s Consensus Guidelines for Anal Cancer Screening. Int. J. Cancer 2024, 154, 1694–1702. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Distribution of the HPV genotypes detected in oral and anal sites. HPV, human papillomavirus.
Figure 1.
Distribution of the HPV genotypes detected in oral and anal sites. HPV, human papillomavirus.
Figure 2.
Differential DNA methylation of ASCL1 (a) and ZNF582 (b) genes in anal samples. Data are expressed as ddCt ratio, as described in Section 2. NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
Figure 2.
Differential DNA methylation of ASCL1 (a) and ZNF582 (b) genes in anal samples. Data are expressed as ddCt ratio, as described in Section 2. NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
Table 1.
Baseline characteristics in persons included in the study.
| Characteristics | |
|---|---|
| Median age, years (IQR) | 49 (38.5–68.0) |
| Median CD4+ T cell count (cells/μL) (IQR) | 705 (486.0–847.0) |
| HIV viral load—N (%) | |
| Undetectable | 51 (80.9) |
| Detectable | 2 (3.2) |
| Unknown | 10 (15.9) |
| Lesion grade | |
| Oral—N (%) | |
| NILM | 30 (47.6) |
| ASCUS | 33 (52.4) |
| Anal—N (%) | |
| NILM | 19 (44.2) |
| ASCUS | 11 (25.6) |
| LSIL | 7 (16.2) |
| HSIL | 6 (14.0) |
Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; IQR, interquartile range (IQR1-IQR3). Viral load is categorized as undetectable for individuals with <30 copies/mL and detectable otherwise per clinical guidelines.
Table 2.
Relative DNA methylation (ddCt values) of FAM19A4 and mir124-2 genes in oral samples.
| Baseline | ddCtFAM19A4 | ddCtmir124-2 | Result | Cytology | Genotype |
|---|---|---|---|---|---|
| Pt 1 | 11.67389416 | - | Negative | ASCUS | HPV16 |
| Pt 2 | 9.453338358 | 11.4266975 | Positive | NILM | HPV82, 39 |
| Pt 3 | 11.33928662 | 14.21413224 | Negative | ASCUS | HPV68 |
| Pt 4 | 9.870100045 | 12.73096119 | Positive | ASCUS | HPV16 |
| Pt 5 | 9.454067616 | - | Positive | ASCUS | HPV16 |
| Pt 6 | 11.8962865 | 11.98879913 | Negative | ASCUS | HPV16 |
| Pt 7 | 10.50086255 | 9.409393794 | Negative | ASCUS | HPV6 |
| Pt 8 | 12.05459854 | 14.7422688 | Negative | NILM | HPV42 |
| Pt 9 | 11.33288572 | 11.13614887 | Negative | ASCUS | HPV18 |
| Pt 10 | 10.9173894 | 10.39343708 | Negative | ASCUS | HPV52 |
| Pt 11 | 12.17853289 | 10.84083335 | Negative | NILM | HPV56,58 |
| Pt 12 | 11.62954436 | 9.511607074 | Negative | ASCUS | HPV35,6 |
| Pt 13 | 12.29596614 | 9.472156942 | Negative | ASCUS | HPV51 |
| Pt 14 | 9.884411623 | 10.75950655 | Positive | NILM | HPV61 |
| Pt 15 | 9.87684043 | 9.049550437 | Positive | ASCUS | HPV53 |
| Pt 16 | 13.2953954 | 10.30919426 | Negative | ASCUS | HPV68 |
| Pt 17 | - | 10.05682617 | Negative | ASCUS | HPV6 |
| Pt 18 | 10.97464054 | 9.605091426 | Negative | ASCUS | HPV31,53 |
| Pt 19 | 10.65275917 | 10.93071802 | Negative | NILM | HPV31,69 |
| Pt 20 | 12.34449267 | 10.59708123 | Negative | NILM | HPV69 |
| Pt 21 | 13.10534787 | 11.00575345 | Negative | ASCUS | HPV26,70 |
| Pt 22 | 12.91008603 | 11.03519112 | Negative | ASCUS | HPV44 |
| Pt 23 | 11.68822231 | 10.68655588 | Negative | ASCUS | HPV16,66 |
| Pt 24 | 10.08326187 | 9.106563818 | Positive | ASCUS | HPV45 |
| Pt 25 | 9.470165301 | 9.55831486 | Positive | NILM | HPV33,35,43 |
| Pt 26 | 14.22511213 | 11.03932987 | Negative | NILM | HPV16 |
| Pt 27 | 7.057501302 | 7.987395465 | Positive | NILM | HPV53 |
| Pt 28 | 10.88859044 | 10.11865056 | Negative | NILM | HPV31 |
| Pt 29 | 11.43293716 | 9.061973272 | Negative | NILM | HPV66 |
| Pt 30 | 8.37381873 | 8.626123558 | Positive | NILM | HPV16 |
| Pt 31 | - | - | Negative | ASCUS | HPV56,58,59,66 |
| Pt 32 | 11.29022259 | 9.572790052 | Negative | NILM | HPV82 |
| Pt 33 | 13.57058146 | 10.62152985 | Negative | ASCUS | HPV11,73 |
| Pt 34 | 14.19290116 | 10.47430333 | Negative | ASCUS | HPV6 |
| Pt 35 | - | 9.556213112 | Negative | NILM | HPV35,61 |
| Pt 36 | - | 13.91914873 | Negative | NILM | HPV68 |
| Pt 37 | 11.44630628 | 9.389119266 | Negative | NILM | HPV53,82 |
| Pt 38 | 10.78752532 | 8.67125565 | Negative | ASCUS | HPV16 |
| Pt 39 | 12.70923461 | 10.12196678 | Negative | ASCUS | HPV6 |
| Pt 40 | 8.7231532 | 7.957266548 | Positive | ASCUS | HPV45 |
| Pt 41 | 10.11 | 9.67 | Positive | NILM | HPV61 |
| Pt 42 | 10.96 | 8.78 | Negative | ASCUS | HPV61 |
| Pt 43 | 12.66397256 | - | Negative | NILM | HPV39,66 |
| Pt 44 | - | 10.10600421 | Negative | NILM | HPV16 |
| Pt 45 | 10.99237382 | 11.43245412 | Negative | ASCUS | HPV58 |
| Pt 46 | 11.69903698 | 9.075850661 | Negative | NILM | HPV52,58 |
| Pt 47 | - | 9.520737204 | Negative | ASCUS | HPV16 |
| Pt 48 | 10.8267296 | 10.43430522 | Negative | NILM | HPV58,73 |
| Pt 49 | 11.41951603 | 13.13531765 | Negative | ASCUS | HPV61 |
| Pt 50 | 11.61742284 | - | Negative | ASCUS | HPV53 |
| Follow-Up | ddCtFAM19A4 | ddCtmir124-2 | Result | Cytology | Genotype |
| FU14 | 10.20468041 | 10.07825271 | Positive | ASCUS | HPV52, HPV61 |
| FU31 | - | - | Negative | NILM | HPV39 |
| FU34 | 13.00001938 | 10.41566436 | Negative | NILM | HPV6 |
| FU44 | - | - | Negative | ASCUS | HPV16 |
Considering the cut-off values used and described in Section 2, we consider a sample “Positive” where the ddCt value of at least one of the two genes is lower than the cut-offs, and “Negative” where the ddCt values of both genes is higher than the cut-off. Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance. High-risk HPV genotypes are indicated in bold. FU, follow-up of some enrolled patients.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Pauciullo, S.; Colombo, D.; Zulian, V.; Sciamanna, R.; Coppola, A.; Scarabello, A.; Del Nonno, F.; Garbuglia, A.R. Association of Methylated DNA Markers with High-Risk HPV Infections in Oral Site and Precancer Anal Lesions in HIV-Positive MSM. Biomedicines 2024, 12, 1838. https://doi.org/10.3390/biomedicines12081838
AMA Style
Pauciullo S, Colombo D, Zulian V, Sciamanna R, Coppola A, Scarabello A, Del Nonno F, Garbuglia AR. Association of Methylated DNA Markers with High-Risk HPV Infections in Oral Site and Precancer Anal Lesions in HIV-Positive MSM. Biomedicines. 2024; 12(8):1838. https://doi.org/10.3390/biomedicines12081838
Chicago/Turabian StylePauciullo, Silvia, Daniele Colombo, Verdiana Zulian, Roberta Sciamanna, Antonio Coppola, Alessandra Scarabello, Franca Del Nonno, and Anna Rosa Garbuglia. 2024. "Association of Methylated DNA Markers with High-Risk HPV Infections in Oral Site and Precancer Anal Lesions in HIV-Positive MSM" Biomedicines 12, no. 8: 1838. https://doi.org/10.3390/biomedicines12081838
APA StylePauciullo, S., Colombo, D., Zulian, V., Sciamanna, R., Coppola, A., Scarabello, A., Del Nonno, F., & Garbuglia, A. R. (2024). Association of Methylated DNA Markers with High-Risk HPV Infections in Oral Site and Precancer Anal Lesions in HIV-Positive MSM. Biomedicines, 12(8), 1838. https://doi.org/10.3390/biomedicines12081838
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
